Health & Biotech

Patrys’ cancer drug worked wonders in mice with breast cancer

December 20, 2018 | Daniel Paproth

News

Lunchtime ASX small cap wrap: who’s still got a job for Christmas

December 20, 2018December 20, 2018 | Daniel Paproth

Health & Biotech

8 biotechs that either flew or sunk on clinical trial results in 2018

December 21, 2018December 20, 2018 | Daniel Paproth

Health & Biotech

Fliers, flameouts and fakers: what happened in biotechland in 2018

December 21, 2018December 21, 2018 | David Langsam

Health & Biotech

Trying to pick the next Biotron or BARD1? Here’s what you need to know

October 25, 2018December 19, 2018 | Rachel Williamson

Health & Biotech

It’s breast cancer awareness month – here are 10 ASX biotechs tackling the disease

October 8, 2018October 8, 2018 | Daniel Paproth

Health & Biotech

Patrys continues brain cancer drug trials – and is also chasing an insurance claim over bung antibodies

August 27, 2018August 27, 2018 | Rachel Williamson

Health & Biotech

Brain cancer fighter Patrys is a 10-bagger – which of these noggin-focused stocks will be next?

July 2, 2018July 2, 2018 | Emma Koehn

News

Lunchtime ASX small cap wrap: who’s keeping up and who’s not

May 31, 2018May 31, 2018 | David Higgins

Health & Biotech

Cancer play Patrys in demand with investors as Harvard Uni collaboration launches

May 22, 2018February 10, 2019 | Special Report

Health & Biotech

Cancer fighter Patrys raises $3.5m in over-subscribed placement

May 16, 2018February 10, 2019 | Special Report

Health & Biotech

Kazia wants to cure the disease that delivered the Trump presidency

April 23, 2018February 10, 2019 | Tim Boreham